Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Resveratrol and its analogues have been investigated for their potential benefits in rheumatoid arthritis (RA) primarily due to their anti-inflammatory and antioxidant properties. Preclinical studies, especially in animal models and in vitro cellular systems, have shown that resveratrol analogues can modulate inflammatory signaling pathways such as NF-κB, reduce the production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6), and inhibit oxidative stress — all of which are relevant to RA pathogenesis. Several analogues, such as pterostilbene and polydatin, have demonstrated similar effects.

However, evidence in humans is limited. There are very few clinical trials assessing the efficacy of resveratrol or its analogues in RA patients. The majority of available research is preclinical, and while promising, does not yet translate into established clinical recommendations. Thus, while there is scientific rationale and some experimental support for the use of resveratrol analogues in RA, the overall level of evidence remains low, and more robust clinical studies are required to confirm efficacy and safety in humans.

More about Resveratrol analogue
More about Rheumatoid Arthritis

Other ingredients used for Rheumatoid Arthritis

Other health conditions supported by Resveratrol analogue

Products containing Resveratrol analogue